Sun Pharmaceutical Industries today said one of its wholly-owned subsidiaries has launched generic metformin hydrochloride extended release tablets, used for glycemic control, in the US market.
The tablets have been launched in the strengths of 500 mg and 1000 mg, it said in a filing to BSE. The tablets are generic versions of Santarus Inc’s Glumetza HCl extended release tablets in the same strengths, it added.
“The addressable market size is approximately $443 million for the 12 months ending April 2018, as per IQVIA,” Sun Pharma said. The tablets are used to improve glycemic control in adults with type 2 diabetes. The Sun Pharma stock was trading 0.24 per cent down at Rs 561.15 in the afternoon on BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.